Nymalize Drop Ship Order Placement and Delivery Schedule
- As a reminder, Nymalize is ordered through your pharmaceutical wholesaler as a drop ship item.
- Drop ship orders for Nymalize placed by your pharmacy through your wholesaler that are received by Safecor Health by the 3pm EST order cutoff time on Monday through Thursday will be shipped for NEXT DAY delivery to your hospital.
- Any Nymalize drop ship order placed through your wholesaler and received by Safecor Health after 3PM EST Monday-Wednesday will be shipped the next business day for overnight delivery to your hospital.
- Nymalize drop ship orders placed through your wholesaler and received by Safecor Health after 3pm EST on Thursdays, as well as any Friday and weekend orders will ship the following Monday by overnight shipping for Tuesday delivery to your hospital.
- Expedited Saturday shipping for emergency situations is possible. If needed, please call Safecor Health at 1-800-447-1006, Option 4 to arrange.
PLEASE NOTE: Expedited Saturday shipments must be requested and orders placed and confirmed by Fridays at 1:30pm EST. Any costs associated with Saturday delivery will be billed to the hospital requesting this service.
To place your order for Nymalize, please contact your wholesaler. (Drop-Ship ONLY)
| Product | NDC | Size | Amerisource Bergen |
Cardinal Health | McKesson | Morris & Dickson |
|---|---|---|---|---|---|---|
| Nymalize® (nimodipine) oral solution  |
24338-260-08 | 8 oz. (237 mL bottle) |
10259389 | 5729660 | 2336071 | 40980 |
| 24338-260-12 | Carton of 12 60 mg/10 mL pre-filled oral syringes |
10235332 | 5630033 | 1531938 | 902452 | |
| 24338-230-12 | Carton of 12 30 mg/5 mL pre-filled oral syringes |
10235333 | 5630025 | 1531920 | 902445 |
If you have any questions, please contact Safecor Health via email at Products@safecorhealth.com or call 1-800-447-1006, and dial Option 4, Monday-Friday, 7:30am-4:30pm EST.
You are encouraged to report side effects of prescription drugs to Azurity Pharmaceuticals, Inc. Medical Information at 1-800-461-7449 or to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
Important Safety Information: Indication and Use
Indication and Use
NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
Blood pressure should be carefully monitored during treatment with Nymalize. Nimodipine may increase the blood pressure-lowering-effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa.
Patients with cirrhosis are at a higher risk of adverse reactions and should be monitored closely and administered a lower dose.
Concomitant use of strong inhibitors of CYP3A4 with nimodipine should generally be avoided because of risk of significant hypotension. These include some macrolide antibiotics (eg, clarithromycin, telithromycin), some HIV protease inhibitors (eg, indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (eg, boceprevir, telaprevir), some azole antimycotics (eg, ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, and nefazodone.
Concomitant use of strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St John’s wort) and nimodipine should generally be avoided, as nimodipine plasma concentration and efficacy may be significantly reduced.
Nimodipine plasma concentration can also be increased in the presence of moderate and weak inhibitors of CYP3A4. If nimodipine is concomitantly administered with these drugs, blood pressure should be monitored, and a reduction of the nimodipine dose may be necessary.
Grapefruit juice inhibits CYP3A4. Ingestion of grapefruit/grapefruit juice is not recommended while taking nimodipine.
Moderate and weak inducers of CYP3A4 may also reduce the efficacy of nimodipine. Patients on these should be closely monitored for lack of effectiveness, and a nimodipine dosage increase may be required.
Common Adverse Reactions
Most common adverse reactions (incidence ≥1% and ≥1% placebo) were hypotension, headache, nausea, and bradycardia.
The Important Safety Information does not include all the information needed to use Nymalize safely and effectively. For additional safety information, please consult the full Prescribing Information for NYMALIZE.
To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
Important Safety Information for Nymalize
Indication and Use
NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
Blood pressure should be carefully monitored during treatment with Nymalize. Nimodipine may increase the blood pressure-lowering-effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa.
Important Safety Information for Nymalize
Indication and Use
NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
Important Safety Information
Blood pressure should be carefully monitored during treatment with Nymalize. Nimodipine may increase the blood pressure-lowering-effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa.
Patients with cirrhosis are at a higher risk of adverse reactions and should be monitored closely and administered a lower dose.
Concomitant use of strong inhibitors of CYP3A4 with nimodipine should generally be avoided because of risk of significant hypotension. These include some macrolide antibiotics (eg, clarithromycin, telithromycin), some HIV protease inhibitors (eg, indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (eg, boceprevir, telaprevir), some azole antimycotics (eg, ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, and nefazodone.
Concomitant use of strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St John’s wort) and nimodipine should generally be avoided, as nimodipine plasma concentration and efficacy may be significantly reduced.
Nimodipine plasma concentration can also be increased in the presence of moderate and weak inhibitors of CYP3A4. If nimodipine is concomitantly administered with these drugs, blood pressure should be monitored, and a reduction of the nimodipine dose may be necessary.
Grapefruit juice inhibits CYP3A4. Ingestion of grapefruit/grapefruit juice is not recommended while taking nimodipine.
Moderate and weak inducers of CYP3A4 may also reduce the efficacy of nimodipine. Patients on these should be closely monitored for lack of effectiveness, and a nimodipine dosage increase may be required.
Common Adverse Reactions
Most common adverse reactions (incidence ≥1% and ≥1% placebo) were hypotension, headache, nausea, and bradycardia.
The Important Safety Information does not include all the information needed to use Nymalize safely and effectively. For additional safety information, please consult the full Prescribing Information for NYMALIZE.
To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.